Hiring in life sciences? Share your open positions with our professional community. Read more Close

Advertisement

Recombinant type III collagen: a promising ingredient for enhancing skin repair post UVB exposure.

Created on 18 Nov 2026

Authors

Qian Wang, Guodong Li, Fei Liu, Hui Liu, Xingkai Wang, Xuan Zhang, Suzhen Yang

Published in

Connective tissue research. Pages 1-14. Nov 17, 2026. Epub Nov 17, 2026.

Abstract

Skin damage is accelerated by UVB exposures. Therefore, it is essential to develop skin repair ingredients to protect the skin from damage caused by UVB exposures. This study was performed to evaluate the efficacy of recombinant type III collagen (RC-III) in alleviating damage induced by UVB exposure, and to elucidate its underlying mechanisms, using the normal human epidermal keratinocytes (NHEKs) and 3D epidermal models (EpiKutis®).
The MTT assay and cell morphology observations were used to assess the cytotoxicity of RC-III. The skin repair potential of RC-III was evaluated on NHEKs and EpiKutis® models by immunofluorescence (IF) staining, Reverse Transcription Quantitative PCR (RT-qPCR), enzyme-linked immunosorbent assay (ELISA), wound closure assay and ultra-high performance liquid chromatography-mass spectrometer (UHPLC-MS/MS).
RC‑III showed no cytotoxicity against NHEKs at a concentration of 2 mg/mL. In the UVB‑damaged models, RC‑III displayed prominent antioxidant effect and anti‑inflammatory property while also modulating the expression of barrier‑related proteins and lipids. Specifically, RC-III could reduce the levels of reactive oxygen species (ROS), increase superoxide dismutase (SOD) activity, decrease the gene and protein expression of inflammatory factors and reduce the protein expression of NF-κB p65, promote the protein expression of peroxisome proliferator-activated receptor alpha (PPARα) and its downstream proteins, and restore the levels of skin lipids.
All findings reported here are derived exclusively from in vitro systems. RC-III showed remarkable skin repair potential, effectively alleviating damage induced by UVB exposure in NHEKs and EpiKutis® models. Our study provided more scientific evidence for the application of RC-III.

PMID:
43046699
Bibliographic data and abstract were imported from PubMed on 18 Nov 2026.

Read full publication at:
Please sign in to see all details.

Advertisement

Stats

  • Community rating n/a 0 votes
  • Reviewers' rating n/a 0 votes
  • Your rating

1-terrible, 9-excellent. How would you rate this publication? Sign in in to submit your rating.

  • Recommendations n/a n/a positive of 0 vote(s)
  • Views 5
  • Comments 0

Recommended by

  • No recommendations yet.

Post a comment

You need to be signed in to post comments. You can sign in here.

Comments

There are no comments yet.

Advertisement